Bristol-Myers Squibb (NYSE: BMY), in many ways, has led the immuno-oncology revolution with its game-changing checkpoint inhibitors Opdivo and Yervoy. However, the stock has lost a bit of its shine in the past year, thanks to …
Bristol-Myers Squibb Co (NYSE:BMY) stock has had a tumultuous 12-month period. In January, it fell 20% but luckily for the bulls it recovered all of it within five weeks. Since then and after several +/-8% moves, BMY is up 12% in 52 weeks …
Bristol-Myers Squibb (NYSE: BMY) investors might have been just a bit worried on Wednesday. After all, the U.S. Food and Drug Administration (FDA) had just placed a partial clinical hold on three clinical trials for Opdivo in combination …
Big pharma stocks have been popular among investors seeking solid dividends for a long time. And for good reason: Large drugmakers historically have generated such tremendous cash flow and earnings that they have been able to reward …
CHICAGO, Sept. 14, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BMY, CLF, HTZ, …
Key highlights in the pharma sector include a complete response letter (“CRL”) from the FDA for Johnson & Johnson’s JNJ investigational rheumatoid arthritis (“RA”) treatment and FDA approval for Merck’s MRK and Bristol-Myers Squibb’s …